We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$614M
AUM Growth
+$229M
Cap. Flow
+$94.5M
Cap. Flow %
15.38%
Top 10 Hldgs %
48.42%
Holding
129
New
38
Increased
24
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$12.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.48M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.95M
4
AZN icon
AstraZeneca
AZN
+$6.54M
5
NICE icon
Nice
NICE
+$5.73M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$50.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$6.5M
4
GSK icon
GSK
GSK
+$6.39M
5
AGN
Allergan plc
AGN
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 57.48%
2 Technology 4.42%
3 Communication Services 1.38%
4 Industrials 1.09%
5 Consumer Discretionary 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
76
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.82M 0.3%
140,000
– –
SMMT icon
77
Summit Therapeutics
SMMT
$10.4B
$1.81M 0.3%
197,450
– –
RPRX
78
DELISTED
Repros Therapeutics Inc.
RPRX
$1.8M 0.29%
+863,807
New +$1.71M
KDNY
79
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.74M 0.28%
28,000
-6,000
-18% -$424K
ALPN
80
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.66M 0.27%
+51,175
New +$1.25M
KERX
81
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.66M 0.27%
311,600
-251,300
-45% -$1.36M
PDSB icon
82
PDS Biotechnology
PDSB
$38.4M
$1.56M 0.25%
7,500
– –
IMDZ
83
DELISTED
Immune Design Corp.
IMDZ
$1.54M 0.25%
203,000
+50,000
+33% +$366K
BURL icon
84
Burlington
BURL
$23.2B
$1.5M 0.24%
+18,500
New +$1.43M
PVLA
85
Palvella Therapeutics
PVLA
$1.99B
$1.48M 0.24%
10,125
– –
SHPG
86
DELISTED
Shire pic
SHPG
$1.45M 0.24%
7,500
-257,039
-97% -$50.1M
VTVT icon
87
vTv Therapeutics
VTVT
$127M
$1.44M 0.23%
+5,000
New +$1.2M
MYOK
88
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.36M 0.22%
+83,240
New +$1.5M
ACIU icon
89
AC Immune
ACIU
$223M
$1.31M 0.21%
+79,800
New +$1.38M
IMMU
90
DELISTED
Immunomedics Inc
IMMU
$1.3M 0.21%
400,000
– –
PTN
91
Palatin Technologies
PTN
$13.7M
$1.2M 0.2%
1,525
+713
+88% +$500K
PANW icon
92
Palo Alto Networks
PANW
$270B
$1.12M 0.18%
+42,312
New +$964K
ABUS icon
93
Arbutus Biopharma
ABUS
$857M
$1.03M 0.17%
300,000
– –
SPNS
94
DELISTED
Sapiens International
SPNS
$1.03M 0.17%
80,844
+19,895
+33% +$260K
MRTX
95
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$992K 0.16%
150,000
– –
OTLK icon
96
Outlook Therapeutics
OTLK
$183M
$850K 0.14%
1,250
-369
-23% -$235K
ARWR icon
97
Arrowhead Research
ARWR
$11.9B
$735K 0.12%
+100,000
New +$648K
ORA icon
98
Ormat Technologies
ORA
$6B
$370K 0.06%
+7,640
New +$361K
ALIM
99
DELISTED
Alimera Sciences
ALIM
$299K 0.05%
+13,381
New +$308K
SITE icon
100
SiteOne Landscape Supply
SITE
$4.12B
$288K 0.05%
+8,020
New +$303K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sphera Funds Management held 129 positions worth $614M, up 59% from $385M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sphera Funds Management deployed $94.5M of net new capital in Q3 2016, opening 38 new positions and adding to 24 existing holdings. Its largest new stake was Sarepta Therapeutics: 263,047 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 77% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Shire pic, an estimated $50.1M trimmed.

  • Sphera Funds Management's largest Q3 2016 buy was Sarepta Therapeutics: 263,047 shares worth $16.2M.
  • Sphera Funds Management added most to Merck in Q3 2016, an estimated $12.3M increase.
  • Sphera Funds Management's biggest Q3 2016 reduction was Shire pic, cutting an estimated $50.1M.
  • Sphera Funds Management fully exited GSK in Q3 2016, selling an estimated $6.39M.
  • Sphera Funds Management's ten largest holdings make up 48% of its $614M portfolio in Q3 2016.
  • Sphera Funds Management opened 38 new positions and closed 23 in Q3 2016.
  • Sphera Funds Management's portfolio value rose 59% quarter-over-quarter to $614M.

Based on Sphera Funds Management's 13F filing for Q3 2016, filed 14 Nov 2016.